| Patent Number |
Title Of Patent |
Date Issued |
| RE34851 |
Biosynthesis of 2 keto-L-gulonic acid |
February 7, 1995 |
| A process of producing 2-keto-L-gulonic acid from sorbose via a recombinant bacteria including expression vectors and probes for producing said recombinant bacteria. |
| RE33887 |
Anti-retroviral compounds |
April 14, 1992 |
| A-B-C wherein A and C are each independently 2',3'dideoxynucleosides and B is a linking group; and a method of treating or preventing a retroviral injection in a subject by administering the compounds of the invention. |
| RE31440 |
Electrochemical electrode with heating means |
November 15, 1983 |
| An electrode arrangement for application to a body surface for bloodless measurement in connection with the concentration or the partial pressure of a gas in the blood comprising a sensor unit having a face member for body contact, and a heating unit coupled to the sensor unit for tr |
| RE30473 |
Benzophenone glycinamide derivatives |
January 6, 1981 |
| This invention is directed toward pharmacologically active compounds of the formula ##STR1## wherein A represents a nitrogen atom which may be substituted by a methyl, cyclopropylmethyl, di(C.sub.1-4 alkyl)aminoethyl, methoxymethyl or hydroxyethyl group and B represents a carbony |
| RE30452 |
3-Phenoxymorphinans and derivatives thereof |
December 16, 1980 |
| Levo-rotary 3-phenoxy N-substituted morphinans and derivatives thereof useful as analgesics and/or narcotic antagonists and their preparation form (-)-3-hydroxy-N-lower alkyl morphinan including intermediates in this preparation. |
| RE30260 |
1-(2,6,6-Trime thyl-3-hydroxy-1-cyclohexen-1-yl)-3-methyl-penta-1,4-diene[or 1-yn-4-en]-3-ols |
April 22, 1980 |
| A total synthesis of canthaxanthin, a known food coloring agent from alpha or retro ionone. |
| RE29842 |
Untriakontapeptide with opiate activity |
November 21, 1978 |
| An untriakontapeptide having significant opiate agonist activity has been isolated from camel pituitary glands. The structure of this peptide has been determined and this peptide was then synthesized utilizing solid phase peptide synthesis. Both natural and synthetic material show id |
| RE29651 |
Derivatives of antibiotic X-537A |
May 30, 1978 |
| Compound of the formula ##STR1## where R.sub.1 is hydrogen, lower alkyl, phenyl, or phenyl substituted by halogen, nitro or lower alkyl; R.sub.2 is hydrogen; lower alkyl; lower alkanoyl; benzoyl; benzoyl substituted by halogen, nitro or lower alkyl; or R.sub.3 is hydrogen, haloge |
| RE29244 |
Coccidiostats |
May 31, 1977 |
| Compositions containing the antibiotic having the designation X-537A, useful for the treatment and prevention of coccidiosis in poultry feed compositions containing the antibiotic and methods of treating coccidiosis are disclosed. |
| RE29163 |
1,2,3,4,10,19-Hexanor-9-oxo-5,9-seco-25D-spirostan-5-oic acid |
March 29, 1977 |
| The spirostan derivative 1,2,3,4,10,19-hexanor-.[.5.]. .Iadd.9.Iaddend.-oxo-5,9-seco-25D-spirostan-5-oic acid is obtained by the microbiological degradation of diosgenin utilizing Proactinomyces restrictus Turfitt CBS 157.45 or enzymes derived therefrom. The aforesaid spirostan deriv |
| RE29003 |
(R)-1-(2-furoyloxy)-3-methylbutyl-penicillin |
October 12, 1976 |
| Compounds represented by the following formula ##EQU1## wherein A is a substituted or unsubstituted heterocyclic radical and T is a C.sub.2 -C.sub.5 alkyl, alkenyl, cyclopropylmethyl, cyclobutylmethyl or cyclopentyl groupA process for their preparation and novel intermediates therefo |
| RE28700 |
Antibiotic X-5108 for stimulating growth |
January 27, 1976 |
| A new antibiotic, designated as antibiotic X-5108, is produced by a new species of streptomyces. The new antibiotic is active against gram-positive and gram-negative bacteria and produces growth stimulation and increased feed efficiency in poultry. |
| D562463 |
Microtiter plate |
February 19, 2008 |
|
| D540665 |
Pharmaceutical package |
April 17, 2007 |
|
| D342793 |
Cuvette |
December 28, 1993 |
|
| D288845 |
Cuvette assembly |
March 17, 1987 |
|
| D287812 |
Safety bottle cap remover |
January 20, 1987 |
|
| D266055 |
Bottle guard |
September 7, 1982 |
|
| D249530 |
Hair microanalyzer |
September 19, 1978 |
|
| 7622492 |
Pyrazolones as inhibitors of 11.beta.-hydroxysteroid dehydrogenase |
November 24, 2009 |
| Provided herein are compounds of the formula (I): ##STR00001## as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment |
| 7619123 |
Methods for stabilizing lithiated halogen-substituted aromatic compounds |
November 17, 2009 |
| The present invention provides novel methods for stabilizing lithiated halogen-substituted aromatic compounds. In particular, the method is useful for the preparation of 2-methoxy-5,6-difluorobenzaldehyde, an important intermediate for the preparation of [4-amino-2-(1-methanesulfonyl |
| 7618973 |
Isoxazolo-pyrazine derivatives |
November 17, 2009 |
| The invention relates to isoxazolo-pyrazine derivatives and their pharmaceutically acceptable salts having affinity and selectivity for the GABA A .alpha.5 receptor binding site, their manufacture, and pharmaceutical compositions containing them. The compounds of present invention ar |
| 7618964 |
Benzamide derivatives, their manufacture and use as pharmaceutical agents |
November 17, 2009 |
| Objects of the present invention are the compounds of formula I ##STR00001## their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as t |
| 7615634 |
4-aminopyrimidine-5-one derivatives |
November 10, 2009 |
| Novel intermediate compounds are disclosed. These compounds are useful in the synthesis of 4-aminopyrimidine-5-one derivatives that inhibit cyclin-dependent kinases, in particular cyclin-dependent kinase 4 (Cdk4). The 4-aminopyrimidine-5-one derivatives and their pharmaceutically acc |
| 7612212 |
Substituted hydantoins |
November 3, 2009 |
| The present invention relates to compounds of the formula ##STR00001## methods for the preparation thereof, and methods for their use. The compounds are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of dis |
| 7612209 |
Pseudo proline dipeptides |
November 3, 2009 |
| Disclosed is a process for the manufacture of pseudo proline dipeptides of the formula ##STR00001## wherein R.sup.1 is a side chain of an alpha amino acid, R.sup.2 is an amino protecting group and R.sup.3 and R.sup.4 are independently either hydrogen or C.sub.1-4-alkyl, and R.sup.5 is |
| 7612099 |
Vinylogous acid derivatives |
November 3, 2009 |
| The invention is concerned with vinylogous acids derivatives of formula (I) ##STR00001## wherein A and R.sup.1 to R.sup.6 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit chymase and can be used as medi |
| 7608721 |
Hexafluoroisopropanol derivatives |
October 27, 2009 |
| The invention is concerned with novel hexafluoroisopropanol derivatives of formula (I) ##STR00001## wherein R.sup.1 to R.sup.6, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind to LXR alpha |
| 7608617 |
Naphthaline derivatives as H3 inverse agonists |
October 27, 2009 |
| The present invention relates to compounds of formula I: ##STR00001## and pharmaceutically acceptable salts thereof, to the preparation of such compounds and pharmaceutical compositions containing them. The compounds are useful for the treatment and/or prevention of diseases which are |
| 7605163 |
Benzoyl-piperazine derivatives |
October 20, 2009 |
| The invention relates to compounds of formula ##STR00001## wherein the substituents are described herein. The compounds may be used in the treatment of illnesses based on the glycine uptake inhibitor, such as psychoses, pain, neurodegenerative disfunction in memory and learning, sch |
| 7601752 |
Pyrrolidine derivatives |
October 13, 2009 |
| The invention is concerned with novel pyrrolidine derivatives of formula (I) ##STR00001## wherein X, Y, R.sup.1, R.sup.2 and R.sup.3 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor |
| 7601711 |
5-amido-indole-2-carboxamide derivatives |
October 13, 2009 |
| The present invention relates to compounds of formula I ##STR00001## wherein G and R.sup.1 to R.sup.5 and R.sup.12 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases whi |
| 7595314 |
Benzoyl-piperazine derivatives |
September 29, 2009 |
| A compound of formula ##STR00001## wherein the substituents are as described in the specification for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as |
| 7592345 |
Piperazine and [1,4]diazepan derivatives as NK antagonists |
September 22, 2009 |
| The present invention relates to a compound of formula I ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.9, R.sup.10, m and n are as defined herein, or to a pharmaceutically acceptable acid addition salt thereof. The present compounds are high potential NK-3 receptor a |
| 7589089 |
Inhibitors for GlyT-1 |
September 15, 2009 |
| The present invention relates to compounds of formula I ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, and X are as defined herein or to pharmaceutically acceptable acid addition salts thereof, with the exception of 4-methoxy-N-[2-oxo-2-(phenylamino)ethyl]-N-phenyl-benzamide, |
| 7585874 |
Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives |
September 8, 2009 |
| The present invention is concerned with aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives of formula I: ##STR00001## wherein R.sup.1 to R.sup.5 are as defined in the specification and pharmaceutically acceptable acid addition salts thereof. This class of compounds has high affin |
| 7582789 |
Ibandronate polymorph |
September 1, 2009 |
| The present invention relates to a new crystalline polymorph of 3-(N-methyl-N-pentyl) amino-1-hydroxypropane-1,1-diphosphonic acid monosodium salt monohydrate (Ibandronate) with the following formula ##STR00001## |
| 7579464 |
Process for preparation of enantiomerically pure compounds |
August 25, 2009 |
| The invention relates to a process for the optical resolution of a dibenzo[b,d]azepinone derivative of formula II, ##STR00001## wherein R.sup.1 is hydrogen or halogen and R.sup.2 is either C.sub.1-4-alkyl optionally substituted with C.sub.3-7-cycloalkyl or benzyl which is optionally |
| 7579369 |
CB 1 receptor inverse agonists |
August 25, 2009 |
| The present invention relates to compounds of formula (I) ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, m and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or |
| 7579351 |
Tricyclic amide derivatives |
August 25, 2009 |
| The present invention relates to compounds of formula I ##STR00001## wherein A, G, r and R.sup.1 to R.sup.5 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are |
| 7579157 |
Antibody selection method against IGF-IR |
August 25, 2009 |
| Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing the antibodies, and uses for the antibodies are disclosed. Antibodies against IGF-IR are implicated in antitumor therapy. |
| 7572823 |
Heteroaryl carboxamide compounds |
August 11, 2009 |
| Compounds of formula I ##STR00001## their manufacture, pharmaceutical compositions containing them and their use as medicaments. |
| 7572809 |
Isoquinoline aminopyrazole derivatives |
August 11, 2009 |
| The present invention relates to the compounds of formula I: ##STR00001## their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of such compounds, pharmaceutical compositions containing them and their manufacture, as we |
| 7572801 |
Pyridopyrimidinone derivatives which are HM74A agonists |
August 11, 2009 |
| The invention is concerned with novel pyridopyrimidinone derivatives of formula (I): ##STR00001## wherein R.sup.1 to R.sup.8, X, Y, m and n are as defined in the description and in the claims. The compounds of the present invention are HM74A agonists with improved properties compared to |
| 7563910 |
Heterocyclic cannabinoid receptor antagonists |
July 21, 2009 |
| The present invention relates to compounds of formula I ##STR00001## and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors. |
| 7563412 |
Reactor for solid phase synthesis |
July 21, 2009 |
| A Reactor (1) for solid phase synthesis comprises a vessel (2), a plurality of filters (3) arranged in the vessel (2) and a plurality of filtrate outlets (4) for evacuating the filtrate out of the filters (3). Each filter (3) is connected to one filtrate outlet (4). The reactor (1) c |
| 7557108 |
(Indol-4-yl) or (indol-5-yl)-piperazinylmethanones |
July 7, 2009 |
| The present invention relates to compounds of formula I ##STR00001## wherein one of R.sup.1 and R.sup.2 is hydrogen and the other one is ##STR00002## and wherein A and R.sup.1 to R.sup.4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The |
| 7553862 |
4-amino-1,5-substituted-1,5-dihydro-imidazol-2-ones |
June 30, 2009 |
| The present invention relates to compounds of formula I ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are as defined herein and to pharmaceutically acceptable acid addition salts thereof. Compounds of formula I or their tautomeric forms are good inhibitors of the glycine |
| 7553833 |
3,3-spiroindolinone derivatives |
June 30, 2009 |
| There are provided compounds of the general formulas ##STR00001## wherein X, Y, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as described herein. The compounds exhibit anticancer activity. |
| 7550487 |
Pyrrolidine-3,4-dicarboxamide derivatives |
June 23, 2009 |
| The invention is concerned with novel pyrrolidine-3,4-dicarboxamide derivatives of formula (I) ##STR00001## wherein R.sup.1 to R.sup.9 and X are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulat |
